The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...

BRAF V600E mutations are common in different tumor ... are currently utilized for the therapy of malignant metastatic melanoma. They include RAF inhibitors, such as sorafenib and vemurafenib ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...

The most pertinent examples are PLX4032 for patients with the BRAF V600E mutation in melanoma and the use of crizotinib (a MET inhibitor that blocks ALK) for the treatment of non-small cell lung ...

One upcoming clinical trial will target the antigen the common BRAF V600E mutation with CD4 T cells in melanoma and other tumors. A second approach is the development of novel therapeutic cancer ...

Despite its high incidence in White patients, advanced melanoma is rare in Asian countries ... The original gene alteration data of Japanese melanomas were converted to the Mutation Annotation Format ...